JERUSALEM–(BUSINESS WIRE)–November 25, 2013– Teva Pharmaceutical Industries (NYSE:TEVA) and Mylan Inc. (NASDAQ:MYL) today announce that certain of their affiliates have agreed to settle and dismiss pending patent litigation involving Copaxone(R) (glatiramer acetate) in the United Kingdom, the Netherlands and France relating to non-infringement and the validity of European Patent 0,762,888, which expires in May 2015. The terms of the settlement are confidential. [
Read More…]
“It’s never good news when your area of the law is on 60 minutes,” says
Courtenay Brinckerhoff, partner at Foley & Lardner LLP at the
2013 AIPLA Annual Meeting. It’s no secret that the Association for Molecular Pathology v. Myriad Genetics case had more than its fair share of media buzz. The decision, holding that isolated DNA was not patent eligible, left many of us wondering how to best address the needs of our biotech clients going forward. [
Read More…]
Invitae Corporation, a genetic diagnostics company, today announced that it plans to defend its right to provide naturally occurring genetic information and services to physicians for their cancer patients through its genetic testing services. Invitae has been named a defendant in a lawsuit filed by Myriad Genetics, Inc. regarding Invitae’s BRCA and MUTYH genetic tests. Invitae disagrees with the allegations of the lawsuit and plans to vigorously defend itself against the lawsuit, which it believes has no merit. [
Read More…]
The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further segmented as insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human
growth hormone; whereas the recombinant glycosylated proteins market is further broken down into erythropoietin, monoclonal antibodies, and follitropin. Calcitonin and glucagon are considered in the recombinant peptides market. [
Read More…]
Mumbai: Biocon Ltd said on Tuesday that the Drugs Controller General of India (DCGI) has given it permission to sell a biological copy of
Herceptin, the world’s best-selling breast cancer drug. The biosimilar trastuzumab, a biological copy of Herceptin, was developed jointly by
Biocon and US generic drug maker
Mylan Inc., and will be sold in India under the brand name
Canmab, Biocon said in a statement on Tuesday. It will be available in India by the fourth quarter of fiscal year 2014. [
Read More…]
Live Industry News
Follow
@C5Live
Join
Life Science & Healthcare Experts: Networking Group
Related Events
For a complete list of all Life Sciences upcoming events:
Click Here Tags: anti corruption, Biosimilars, biotech patenting, Life Sciences, Medical Device, patent litigation, Pharma Patenting